Andrew Doré is a Senior Research Leader in Structural Biology at Isomorphic Labs, where they have been driving innovation since 2025. Previously, Andrew served as Vice President at CHARM Therapeutics from 2022 to 2025 and as Director of Crystallography at Heptares from 2015 to 2022. With a DPhil in Protein Crystallography from the University of Cambridge, they have a distinguished record in structural biology, leading multidisciplinary teams to secure significant pharmaceutical alliances and translating critical structural insights into therapeutic pipelines. Andrew has also co-founded Structural Insights Consulting Group LLP in 2025 and held various prominent roles in the field, contributing significantly to research and mentorship.
This person is not in the org chart
This person is not in any teams
This person is not in any offices